How intravascular direct visualization closes the diagnostic gap that calcium scoring cannot.

The coronary artery calcium score, or CAC, has earned its place in cardiovascular medicine. It is fast, noninvasive, inexpensive, and validated by decades of research. The 2018 AHA/ACC cholesterol guidelines integrated it as a decision-making tool for borderline-risk patients. Millions of Americans have had the scan. Awareness of arterial disease burden has never been higher.

But awareness is not the same as understanding. And a number, no matter how precise, is not the same as a picture.

That distinction matters enormously. And the data are unambiguous about where the calcium score ends and where the real clinical work begins.

What the calcium score actually measures

A CAC scan detects calcified plaque. Calcium deposits form over time as the body attempts to stabilize atherosclerotic lesions. The Agatston score quantifies those deposits and translates them into a risk category. A score above 100 generally warrants intensified medical therapy. A score above 400 is considered high-risk. The test takes roughly 10 minutes and delivers a radiation dose comparable to a screening mammogram.

None of that is in dispute. The problem is what the calcium score cannot see.

The British Columbia Medical Journal summarized it plainly: CAC identifies only calcified plaque and does not differentiate between stable and unstable plaque. The composition of plaque is crucial to understanding true cardiovascular event risk. A score of zero does not rule out the presence of non-calcified, potentially dangerous lesions.

Source: BCMJ, Early Detection and Lasting Prevention: The Significance of Coronary Artery Calcium Scores, 2025

The False Reassurance Problem

This is where the supplement advertorial circulating on social media gets something fundamentally right, even if it gets everything else wrong: patients with a "normal" calcium score can still be at serious acute risk. The difference is that cayenne pepper softgels do not solve that problem. Direct intravascular visualization does.

The numbers are sobering.

A 2008 study published in the American Journal of Roentgenology examined 729 patients who had both a calcium score and a CT angiogram. Of the 325 patients with a normal calcium score, 51 percent had non-calcified plaque on coronary CTA. More than 3 percent had at least moderate stenosis. Some had severe stenosis. A low calcium score had provided false reassurance in a clinically meaningful number of patients.

Source: Kelly et al., American Journal of Roentgenology, July 2008

The Miami Heart Study corroborated this. Among 2,359 asymptomatic individuals, 15 percent of those with a zero-calcium score had noncalcified atherosclerotic plaque on advanced imaging. The SCAPIS trial, which examined more than 30,000 individuals ages 50 to 64, found that 5.5 percent of those with a zero-calcium score harbored noncalcified plaque.

Source: Cardia Vision retrospective analysis, 2025; Nasir K. et al., Miami Heart Study, 2022; Bergstrom G. et al., SCAPIS trial, 2021

The SCOT-HEART trial added a critical clinical dimension: non-calcified plaque is more likely to rupture than calcified plaque. The dangerous lesion is often the one the calcium score misses entirely.

Source: Williams MC et al., SCOT-HEART trial findings, 2020

The Cleveland Clinic states the issue directly. The calcium score shows calcification in coronary arteries that have plaque buildup, but it cannot detect soft plaque atherosclerosis and is therefore not absolute in predicting heart attack or stroke risk. It is one tool among several. The composition of plaque determines vulnerability. A score alone cannot tell you that.

Source: Cleveland Clinic, Calcium Score Screening Heart Scan, 2023

What Coronary Angiography Also Cannot Tell You

When a calcium score comes back elevated, the next step is typically coronary angiography. This has been the gold standard for procedural guidance for 50 years. But its limitations are well documented.

Angiography is a lumenogram. It shows the shadow of blood flowing through a vessel. It does not show the vessel wall. It cannot characterize plaque morphology. It cannot identify a thin fibrous cap, a lipid-rich necrotic core, or a lesion at high risk for rupture that is not yet flow-limiting. Because arteries undergo outward remodeling to accommodate early plaque, significant atherosclerotic burden can exist without any visible narrowing of the lumen at all.

Glagov's remodeling phenomenon, described in landmark research from the 1980s, explains why angiography consistently underestimates early disease. The vessel expands outward before the lumen narrows. The problem hides in plain sight.

A systematic review published in the Journal of Geriatric Cardiology (2024) confirmed this. Coronary angiography has long been the standard for coronary imaging, but it has fundamental limitations in assessing vessel wall anatomy and guiding percutaneous coronary intervention. Intravascular imaging overcomes these limitations by enabling direct cross-sectional visualization of the vessel interior.

Source: Role of Intravascular Ultrasound and OCT in Intracoronary Imaging, Journal of Geriatric Cardiology, January 2024

The Evidence for Intravascular Imaging-Guided Intervention

The clinical trial evidence supporting intravascular imaging-guided PCI has accumulated rapidly and is now reflected in the highest tier of guideline recommendations.

The OCTIVUS Trial (Circulation, 2023)

This prospective, multicenter trial randomized 2,008 patients to either OCT-guided or IVUS-guided PCI. Both modalities produced comparable outcomes with low rates of major adverse cardiovascular events at one year. The trial confirmed that intravascular imaging guidance is safe and effective across the vast majority of PCI procedures. It also reinforced the established evidence that imaging-guided PCI is superior to angiography-guided PCI for high-risk and complex lesions.

Source: OCTIVUS Randomized Clinical Trial, Circulation (AHA Journals), 2023

The RENOVATE-COMPLEX-PCI Trial

This landmark trial showed that imaging-guided PCI (using either IVUS or OCT) significantly reduced the composite of cardiac death, target vessel myocardial infarction, and clinically driven target vessel revascularization compared to angiography-guided PCI in patients with complex coronary lesions. The difference was clinically meaningful and statistically robust.

Source: RENOVATE-COMPLEX-PCI, multiple publications, 2023-2024

2025 Network Meta-Analysis (JACC: Cardiovascular Interventions)

A January 2026 meta-analysis covering multiple complex lesion types found that intravascular imaging guidance cut MACE risk by approximately 37 percent compared to angiography alone in OCT-guided procedures (RR 0.63) and by approximately 33 percent in IVUS-guided procedures (RR 0.67). The analysis covered CTOs, bifurcation lesions, left main disease, multivessel disease, and heavily calcified lesions. Both modalities outperformed angiography across all major lesion subtypes.

Source: IVUS, OCT, or Angiography as Guidance for PCI in Complex Coronary Artery Lesions, JACC: Cardiovascular Interventions, 2025

Source: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes, Circulation, 2025

The PREVENT Trial: Direct Visualization as a Preventive Tool

The most compelling recent evidence for the role of intravascular imaging in cardiovascular prevention comes from the PREVENT trial, published in The Lancet in May 2024. It is the first large-scale randomized controlled trial to demonstrate that preventive PCI of non-flow-limiting vulnerable plaques, identified by intravascular imaging, significantly reduces adverse cardiac events.

The trial enrolled 1,606 patients at 15 centers across South Korea, Japan, Taiwan, and New Zealand. All patients had plaques that were angiographically significant (more than 50 percent stenosis by visual estimation) but hemodynamically non-significant by fractional flow reserve testing. Standard clinical practice would have left these lesions untreated.

Vulnerable plaque was defined by intravascular imaging criteria: a minimal lumen area below 4.0 mm squared by IVUS or OCT, plaque burden above 70 percent, thin-cap fibroatheroma identified by OCT or virtual histology IVUS, or lipid-rich plaque detected by near-infrared spectroscopy. Patients meeting at least two of these criteria were randomized to preventive PCI plus optimal medical therapy, or optimal medical therapy alone.

Source: Park SJ et al. (PREVENT Investigators). Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT). The Lancet, 403(10438):1753-1765, May 2024.

The key enabler of that benefit was intravascular imaging. Without the ability to characterize plaque morphology at the vessel wall level, the vulnerable lesions would have been invisible. Angiography alone would not have identified them as targets for intervention.

A PMC analysis summarizing the trial noted that advances in intracoronary imaging have improved identification of vulnerable plaques characterized by large plaque burden, small minimal lumen area, thin fibrous cap, and large lipid content. These are characteristics undetectable by coronary angiography.

Source: Management of Coronary Vulnerable Plaque with Medical Therapy or Local Preventive PCI, PMC, June 2024

The ACC's commentary on PREVENT was direct: the trial opens the door to an additional benefit of PCI based on carefully selected imaging criteria. It demonstrates that intravascular imaging can identify who is at risk before an event occurs, not just after.

Source: ACC.org, PREVENT trial clinical trial summary, April 2024

The Diagnostic Chain: From Alarm to Answer

The journey from cardiovascular concern to clinical clarity has historically involved too many gaps. The calcium score identifies a problem. Angiography shows the plumbing. But neither one tells you the wall itself is in danger.

That is the chain we are working to close.

The Scanning Fiber Endoscope: Direct Visualization Where It Matters Most

INVESTIGATIONAL DEVICE. Not FDA cleared. Future clinical capabilities described below are subject to FDA 510(k) review.

The Scanning Fiber Endoscope platform, in development at VerAvanti, Inc., is designed to address precisely the diagnostic gap that the calcium score, CTA, and conventional angiography leave open.

Rather than estimating plaque burden from outside the vessel or inferring risk from a population-level score, the SFE platform is designed to provide direct intravascular visualization with unprecedented miniaturization. The platform is intended to be navigated through coronary, neurovascular, and peripheral vessels to provide real-time, high-resolution imaging of the vessel wall, the lesion morphology, and the procedural field.

Designed for the Procedures Where Visualization Matters Most

VerAvanti's initial commercial focus centers on chronic total occlusion crossing and bifurcation PCI. Both are precisely the complex lesion types where the meta-analysis evidence is clearest: intravascular imaging-guided PCI reduces MACE by more than 30 percent compared to angiography guidance alone.

In CTO procedures, the path through the occluded segment is navigated by feel and by angiographic inference. Intravascular imaging is designed to allow the interventionalist to see that path directly, reducing the likelihood of vessel perforation, subintimal wiring, and failed crossing attempts. In bifurcation lesions, stent optimization is complex. Imaging guidance is designed to verify apposition, identify dissections, and confirm expansion before the catheter is withdrawn.

A Head-to-Toe Investigational Platform

The SFE platform is designed as a head-to-toe intravascular and endoluminal imaging system. The same core technology is intended for cardiovascular, neurovascular, and peripheral vascular applications. Miniaturization enables access to vessel territories that current imaging catheters cannot reliably reach.

This matters for the PREVENT trial framework. As intravascular imaging moves toward a preventive role, the ability to navigate smaller, more distal vessels will determine which patient populations can benefit. A platform designed for head-to-toe coverage expands that population significantly.

Closing the Loop from Calcium Score to Clinical Action

Here is the practical clinical workflow the SFE platform is designed to support, pending FDA clearance:

•       Patient presents with a CAC score in the 100 to 1,000 range, or with risk factors warranting further workup.

•       Coronary CTA or invasive angiography identifies lesions of potential concern.

•       Intravascular imaging with the SFE platform is used to characterize lesion morphology, cap thickness, plaque composition, and minimal lumen area.

•       The interventionalist makes a treatment decision based on direct visual evidence: optimize medical therapy, proceed with preventive PCI, or plan a revascularization procedure with real-time imaging guidance.

•       In procedures where stenting is performed, the SFE platform is designed to confirm stent deployment, apposition, and expansion before the case is closed.

The calcium score started that workflow. The SFE platform is designed to complete it.

Why This Moment Matters

The supplement marketing ecosystem has identified a real anxiety and exploited it. Millions of patients with elevated calcium scores are told their risk is increasing and their options are limited. They are often correct on the first point. They are wrong on the second.

The evidence from PREVENT, from RENOVATE, from OCTIVUS, and from the updated 2025 ACC/AHA guidelines all point in the same direction. Intravascular imaging is not a luxury for complex cases. It is a clinical standard for patients who need more than a score and a statin.

The calcium score sounded the alarm. Direct visualization is the flashlight.

One number tells you something is wrong. One image tells you what it is, where it is, and what to do about it. That is the clinical problem VerAvanti is building technology to solve.

Supporting References

1. AHA/ACC 2018 Guideline on the Management of Blood Cholesterol. Grundy SM et al. J Am Coll Cardiol. 2019;73(24):e285-e350.

2. Kelly JC et al. Calcium score has place, but CTA soft plaque imaging identifies silent risk. American Journal of Roentgenology, July 2008.

3. Early Detection, Lasting Prevention: The Significance of Coronary Artery Calcium Scores. British Columbia Medical Journal, 2025.

4. Retrospective analysis: CCTA vs. CAC scoring in 100 consecutive patients. Cardia Vision, LLC, Bellevue WA, 2025.

5. Nasir K et al. Miami Heart Study. Noncalcified plaque in CAC=0 individuals, 2022.

6. Bergstrom G et al. SCAPIS trial, 2021. JACC/ESC publication.

7. Williams MC et al. SCOT-HEART trial: Non-calcified plaque and rupture risk, Eur Heart J, 2020.

8. OCTIVUS Randomized Clinical Trial. OCT-guided vs. IVUS-guided PCI. Circulation (AHA Journals), 2023.

9. RENOVATE-COMPLEX-PCI Trial. Intravascular imaging vs. angiography-guided PCI. JACC/Circulation, 2023-2024.

10. Carvalho PEP et al. IVUS, OCT, or Angiography as Guidance for PCI in Complex Coronary Artery Lesions: Network Meta-Analysis of RCTs. JACC: Cardiovascular Interventions, 2025 (published TCTMD Jan 2026).

11. Giacoppo D et al. Coronary Angiography, IVUS, and OCT for Guiding PCI: Systematic Review and Network Meta-Analysis. Circulation, 2024;149:1065-1086.

12. Role of intravascular ultrasound and OCT in intracoronary imaging for coronary artery disease: a systematic review. J Geriatr Cardiol. 2024;21(1):104-129.

13. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes. Rao SV et al. Circulation. 2025;151:e771.

14. Park SJ et al. (PREVENT Investigators). Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT). The Lancet. 2024;403(10438):1753-1765.

15. Management of Coronary Vulnerable Plaque with Medical Therapy or Local Preventive PCI. PMC/J Soc Cardiovasc Angiogr Interv. June 2024.

16. Intravascular Coronary Imaging Update: Advances, Clinical Applications, and Future Directions. Current Cardiology Reports. July 2025.

17. Intravascular imaging for acute coronary syndrome. npj Cardiovascular Health, May 2025.

IMPORTANT NOTICE: The Scanning Fiber Endoscope is an investigational device. It is not cleared or approved by the U.S. Food and Drug Administration. Clinical capabilities described herein represent intended future functionality pending FDA 510(k) review and clearance. This document is intended for educational and research purposes only and does not constitute the promotion of an investigational device.